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Imaging studies in animals and in humans have indi-
cated that the oxygenation and nutritional status of
solid tumors is dynamic. Furthermore, the extremely
low level of glucose within tumors, while reflecting
its rapid uptake and metabolism, also suggests that
cancer cells must rely on other energy sources in
some circumstances. Here, we find that some breast
cancer cells can switch to utilizing lactate as a pri-
mary source of energy, allowing them to survive
glucose deprivation for extended periods, and that
this activity confers resistance to PI3K/mTOR inhibi-
tors. The nuclear receptor, estrogen-related receptor
alpha (ERRa), was shown to regulate the expres-
sion of genes required for lactate utilization, and
isotopomer analysis revealed that genetic or phar-
macological inhibition of ERRa activity compromised
lactate oxidation. Importantly, ERRa antagonists
increased the in vitro and in vivo efficacy of PI3K/
mTOR inhibitors, highlighting the potential clinical
utility of this drug combination.
INTRODUCTION
Increased glucose uptake and aerobic glycolysis are character-
istics of transformed cells that have been exploited in the devel-
opment of cancer therapeutics (Dang et al., 2011; Warburg
et al., 1927). Not generally appreciated, however, is the fact
that glucose levels are usually extremely low (<1mM) within solid
tumors (Hirayama et al., 2009; Ho et al., 2015; Urasaki et al.,
2012). This implies that solid tumors are likely to be in a constant
state of metabolic stress, and they must have the ability to adapt
to alterations in glucose availability. Interestingly, intratumoral
levels of lactate (5–10 mM) are much higher than glucose in
many different tumor types (Kennedy et al., 2013; Schroeder
et al., 2005; Walenta et al., 2003). The potential significance of
this observation has been highlighted in recent studies which
demonstrated that lactate produced by glycolytic cells withinThis is an open access article under the CC BY-Nthe hypoxic regions of tumors, or by cancer associated fibro-
blasts, can be taken up by cells in more oxygenated regions of
the tumor where it is further oxidized to produce ATP (Boidot
et al., 2012; Pavlides et al., 2009; Sonveaux et al., 2008). These
findings, as well as the results of additional studies, have high-
lighted the importance of functional mitochondria in cancer
pathogenesis (Viale et al., 2015).
Under glucose replete conditions, most cancer cells are glyco-
lytic and increases in the demand for ATP production can bemet
by enhancing glycolytic flux (Pfeiffer et al., 2001). However, the
observations that glucose is generally limiting within tumors
and that oxygen tension is both spatially and temporally dynamic
suggests that the ability to engage mitochondria for energy
production in tumors are also likely to be important. Indeed,
accumulating evidence suggests that cancer cells utilize both
glycolysis and mitochondrial oxidative metabolism to satisfy
their metabolic demands (Koppenol et al., 2011; Zu and Guppy,
2004). This conclusion would appear to be at odds with the
observation that most cells within tumors are in regions of
hypoxia where oxygen-dependent oxidative phosphorylation
(OXPHOS) was assumed to be inactive. However, it has been
shown that mitochondrial oxidative phosphorylation is active
within cells located in environments with oxygen levels as low
as 0.5% (Chandel et al., 1996; Rumsey et al., 1990; Weinberg
and Chandel, 2015). This suggests that even within hypoxic
regions of tumors complete oxidation of glucose (and lactate)
are not only possible, but also are likely to be important for tumor
cell viability.
The observation that mitochondria play a key role in tumori-
genesis has driven efforts to identify cancer chemotherapeutics
that function by targeting oxidative metabolism (Weinberg and
Chandel, 2015). Notable is the interest in the potential anticancer
activities of metformin, a widely prescribed antidiabetic drug that
can inhibit complex I within the mitochondrial electron transport
chain (ETC) (Dowling et al., 2011; Foretz et al., 2014). Notwith-
standing the potential utility of metformin in cancer, there is a
need for additional therapeutics that interfere with mitochondrial
function in a manner that minimizes the impact on normal cells.
The estrogen-related receptor alpha (ERRa), a druggable tran-
scription factor that regulates mitochondrial biogenesis and
function, is thus a potentially useful therapeutic target.Cell Reports 15, 323–335, April 12, 2016 ª2016 The Authors 323
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ERRa is expressed in most cancers and increased activity of
this receptor is associated with a negative outcome in breast
and ovarian cancers (Chang et al., 2011; Fujimoto et al., 2007;
Lam et al., 2014; Suzuki et al., 2004). This transcription factor
has been shown to be involved in mitochondrial biogenesis
and in the regulation of OXPHOS (Chang et al., 2011; Charest-
Marcotte et al., 2010; Huss et al., 2007). Given the restricted na-
ture of its expression, and the subtle phenotypes in animals in
which this receptor is ablated, we considered that inhibition of
its activity would enable a selective disruption of mitochondrial
function in cancer. In this study, it is demonstrated that the ability
of breast cancer cells to oxidize lactate is essential for viability
under conditions of glucose deprivation, and that disruption of
mitochondrial function using ERRa antagonists inhibits lactate
utilization. It was further demonstrated that most breast cancer
cells that actively engage OXPHOS are insensitive to the inhibi-
tory effects of PI3K/mTOR inhibitors, but that the efficacy of
these targeted therapies can be enhanced by coadministration
of an ERRa antagonist. The clinical utility of PI3K inhibitors has
been restricted by their dose limiting toxicities (Bendell et al.,
2015; Burris et al., 2010). Thus, it was significant that we could
show in vivo that the effective dose of select PI3K inhibitors
could be reduced using drug regimens that included an ERRa
antagonist.
RESULTS
Evaluation of the Impact of Lactate Metabolism on
Processes of Pathological Importance in Cellular
Models of Breast Cancer
There is a high level of interest in defining metabolic vulnerabil-
ities in cancers that can be exploited in the development of
new therapeutics. Much of this effort has focused on developing
strategies to effect a useful inhibition of glycolysis, although the
recent definition of essential roles for mitochondrial function in
cancer pathogenesis has highlighted new opportunities for inter-
vention. Notable is the observation that although cancer cells are
avid consumers of glucose, intratumoral levels of glucose are
usually exceedingly low (Hirayama et al., 2009). Under these cir-
cumstances of low glucose, tumor cells can take up and oxidize
lactate (Sonveaux et al., 2008). However, the role(s) that lactate
plays in cancer pathogenesis, its metabolic fate, the pathways
that regulate its utilization, and the impact of manipulating those
pathways remain important issues to be addressed.
Considering the paucity of therapeutics available for patients
with triple negative breast cancer (TNBC), we first explored
lactate biology in cellular models of this disease. In preliminary
studies it was observed that when grown in different concen-
trations of glucose, MDA-MB-436 (MDA436) cells (a model of
TNBC) produced lactate, but switched from net lactate pro-
ducers to consumers when glucose was limiting (Figure S1A).
The importance of this observation was evaluated by growing
MDA436 cells in the presence of different concentrations of
glucose in the absence or presence of 10 mM sodium lactate
and assessing cell growth/viability. As shown in Figure 1A, cell
viability was unaffected by lactate in high glucose conditions
(12.5 mM; standard media conditions). Viability was compro-
mised, however, when cells were grown in lower glucose con-324 Cell Reports 15, 323–335, April 12, 2016centrations, but this was mitigated by supplementation with
lactate or methyl pyruvate (MP; a mitochondrial permeable
form of pyruvate) (Figures 1A and S1B). Using the same experi-
mental paradigm, it was demonstrated that lactate was similarly
protective in a large number of cell lines that model different sub-
types of breast cancer (Figures 1B and S1C). Annexin V staining
of lactate (or MP) treated cells confirms that the protection of
cell viability observed can be attributed to reduced apoptosis
(Figures 1C and S1D). Not unexpectedly, cellular ATP levels
were maintained by lactate supplementation when glucose
was withdrawn from cells (Figure 1D). The potential biological
significance of these findings was revealed in studies where cells
were maintained in the absence or presence of lactate for 6 days
(without media change), at which time they were supplemented
with glucose. As shown in Figures 1E and S1E, those cells that
were maintained in lactate (or MP) were able to proliferate
upon glucose refeeding, suggesting that lactate serves to main-
tain cell viability until glucose becomes available.
Lactate Serves as a Respiratory Substrate in Cancer
Cells when Glucose Is Limiting
Whereas we and others have shown that lactate can serve as a
fuel source when glucose is limiting, there remains disagreement
in the field as to whether it enters the tricarboxylic acid (TCA) cy-
cle directly or if it must first be converted to glucose through
gluconeogenesis (Leithner et al., 2015). Whereas some cancer
cells do have the ability to support gluconeogenesis (Chen
et al., 2015; Leithner et al., 2015), we demonstrated that the pro-
tective effect of lactate (andMP) inMDA436 cells was unaffected
by small interfering (si)RNA-mediated knock down of pyruvate
carboxylase, the first anaplerotic enzyme in the gluconeogenic
pathway (Figures 2A and S2A). This suggested that pyruvate
was serving as a catabolic substrate in glucose deprived cells,
and that it relied on the activity of the pyruvate dehydrogenase
(PDH) complex to enter the TCA cycle. We demonstrated that
the PDH complex is active in low glucose conditions (hypophos-
phorylation at serine 293 of the E1 alpha subunit of the PDH
complex), and that it remains active upon the addition of lactate
or MP (Figure 2B). It was also shown that the protective effect
of lactate on cell viability required PDH activity (Figures 2C
and S2B).
Demonstration that 14C-labeled CO2 is released fromMDA436
cells that were incubated with [U-14C]-lactate confirms that
lactate can enter the TCA cycle (Figure 2D). Further, a previously
published survey of [3-13C]-lactate metabolism in vitro and
in vivo using nuclear magnetic resonance also indicated that
lactate can be transported into and oxidized in cancer cells
(Gallagher et al., 2009; Kennedy et al., 2013). Although confirm-
ing that lactate can be utilized, these studies do not provide a
quantitative assessment of lactate entry into the TCA cycle,
information that would help to evaluate its importance as a
respiratory substrate. Thus, we undertook a comprehensive iso-
topomer analysis using [U-13C]-labeled lactate in MDA436
and HCC1937 cells. In MDA436 cells, it was determined that
(1) under conditions of glucose deprivation, over 50% of the
total cellular pool of TCA cycle intermediates were derived
from lactate; (2) alanine, glutamate, and aspartate, amino acids
generated from pyruvate or from other TCA cycle intermediates
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Figure 1. Lactate Enables Cancer Cells to Withstand Glucose Deprivation
(A)MDA436 cells were seeded in 96-well plates and 48 hr later were changed to themedia as indicated. The cells were then harvested at the time points indicated,
and cell numbers were determined by staining with Hoechst 33258.
(B) Cells were seeded in 96-well plates and 48 hr later were changed to glucose-free media supplemented with (Lac) or without (Veh) 10 mM sodium lactate. The
cells were then harvested, and cell number was determined by staining with the DNA dye Hoechst 33258.
(C) MDA436 cells were incubated with vehicle (Veh) or 10 mM sodium lactate (Lac) in glucose-free RPMI media for 24 hr. The harvested cells were stained with
Alexa Fluor 488-Annexin V+Sytox Red dye and analyzed by flow cytometry.
(D) ATP content was determined over time inMDA436 cells cultured in the indicatedmedia using a bioluminescence assay. The error bars represent SD (statistical
significance No Glc versus No Glc+Lac) (**p < 0.05).
(E) MDA436 cells were cultured in glucose-free media supplemented with or without 10 mM sodium lactate for 6 days and vehicle (Veh; media) or glucose
(Glc; final 12.5 mM) was added back to culture media at day 6 and harvested on days as indicated. The cell number was determined by staining Hoechst
33258.
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Figure 2. Lactate Is Oxidized by Cancer Cells
(A and C) MDA436 cells were transfected with control (siCtrl), (A) PC (siPC-B and siPC-C), or (C) PDHA-1 (siPDHA1-A and siPDHA1-B) siRNAs for 48 hr. The cells
were then switched to glucose-free media with or without lactate (Lac) and harvested as indicated. The cell numbers were determined by staining with the DNA
dye Hoechst 33258 (PDH alpha 1: PDHA1 and pyruvate carboxylase: PC).
(B) MDA436 cells were incubated in the indicated media for 4 hr, and whole-cell extracts were analyzed by immunoblotting to determine the status of PDH
phosphorylation by PDH-E1a (pSer293) antibody. Total PDH-E1a was used as a loading control.
(D) Isotopically labeled lactate was added to MDA436 cells that were grown in glucose-free media supplemented with 10 mM sodium lactate for 24 hr and the
generation of 14CO2 from [U-
14C]-lactate was measured. A cell-free sample containing [U-14C]-lactate was included as a negative control (N.Ctrl).
(E) Relative metabolite abundance in MDA436 cells grown in glucose-free media supplemented with 10 mM of [U-13C]-lactate for 6 hr. The data are presented as
the percentage of 13C-labeled metabolite pool. The error bars represent SD of three experimental replicates.
(F) A schematic representation of malate-aspartate shuttle (left). MDA436 cells were transfected with control (siCtrl) or MDH1 (siMDH1-A and siMDH1-B) siRNAs
for 48 hr. The cells were then switched to glucose-free media with or without lactate (Lac) and harvested on days as indicated (right).were also heavily enriched with the 13C label; (3) significant
labeling of phosphoenolpyruvate (PEP) was observed although
fructose 1,6-bisphosphate (FBP), hexose-phosphate (G6P),
and glucose (Glc) were almost undetectable; (4) pyrimidines
(UTP and CTP), derived from aspartate, were also labeled with326 Cell Reports 15, 323–335, April 12, 201613C, but no labeling of purines was detected; and (5) only low
amounts of the 13C label were incorporated into fatty acids (Fig-
ure 2E). Similar results were observed in HCC1937 cells (Fig-
ure S2C). Together, these data suggest that in the absence of
glucose, lactate contributes significantly to the TCA cycle and
AB C
Figure 3. Lactate Utilization Requires Gluta-
mine to Protect Cells from ROS
(A) MDA436 cells were incubated with glucose and
glutamine-free DMEM (10% dialyzed FBS) supple-
mented with vehicle (No Lac), glucose (Glc), or
lactate (Lac) alone or in combination with either GSH
or glutamine (Gln) for 24 hr. The cells were then
incubated with CM-H2DCFDA for 60 min, and the
intensity of fluorescence was measured using flow
cytometry.
(B) MDA436 cells were seeded in 96-well plates and
48 hr later were changed to glucose and glutamine-
free DMEM (10% dialyzed FBS) supplemented with
vehicle (Veh; media), 10 mM lactate (Lac), 2 mM
glutamine (Gln), 10 mM GSH reduced, or in combi-
nation. The cells were then harvested on days
as shown, and cell numbers were determined by
staining with the DNA dye Hoechst 33258.
(C) The generation of 14CO2 from [U-
14C]-lactate was
measured from MDA436 cells grown in the media
as shown for 24 hr. The data shown are represen-
tative of three independent experiments. The error
bars represent SD (statistical significance Lac versus
Lac+Gln) (**p < 0.05).anaplerosis, but does not undergo gluconeogenesis in these
model systems.
One question that arises from the results of the studies above
is how cancer cells regenerate the NAD+ needed to enable the
sustained production of pyruvate from lactate. It was significant,
therefore, that we determined that the protective effect of lactate
in MDA436 cells was reduced by siRNA-mediated knock down
of malate dehydrogenase (MDH1), suggesting that the malate-
aspartate shuttle was likely to play a significant role in regenerat-
ing the cytosolic NAD+ needed for lactate oxidation (Figure 2F).
Lactate Utilization Requires Glutamine to Attenuate
Reactive Oxygen Species Production
The production of mitochondrial reactive oxygen species (ROS)
is a significant liability of oxidative metabolism in that it can lead
to mitochondrial damage, genome instability, and contribute
to resistance to chemotherapeutics (Liou and Storz, 2010). It
was of interest, therefore, that we observed significant ROS pro-
duction in cells grown in no glucose RPMI (containing 2 mMglutamine), a likely consequence of the
oxidation of endogenous respiratory sub-
strates. Not unexpectedly, ROS was low
under the same conditions when cells
were supplemented with 12.5 mM glucose.
Surprisingly, using the same experimental
paradigm (RPMI containing 2 mM gluta-
mine), lactate was as effective as glucose
in suppressing basal ROS production
(Figure 3A, left). A potential explanation
for this observation came from the iso-
topomer experiments, where it was deter-
mined that the reduced glutathione (GSH)
pool was derived from both 13C-lactate
and 13C-glutamine in glucose free condi-tions, raising the possibility that together, lactate and glutamine
present in the media, are sufficient to overcome ROS production
associated with lactate oxidation (Figures S3A and S3B). To
address this possibility, we repeated the studies in glutamine
free media (Figure 3A, center). The informative results of this
experiment indicated that whereas glucose alone was capable
of suppressing ROS production, lactate, absent glutamine,
was unable to achieve the same result. The observation that
the addition of GSH obviated the need for glutamine suggests
that one of its roles in lactate fueled cells is to contribute reducing
equivalents to attenuate ROS production (Figure 3A, right).
Thus, whereas glutamine is important for anapleurosis and can
contribute to cell biomass in proliferating cells through oxidative
and reductive carboxylation, it appears that it also plays an
essential role in lactate support of cell viability in low glucose
conditions. This hypothesis was confirmed in lactate comple-
mentation studies where it was demonstrated that the ability of
lactate to support cell viability (Figure 3B) and prevent apoptosis
(Figure S3C) in the absence of glucose required glutamine orCell Reports 15, 323–335, April 12, 2016 327
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Figure 4. PGC1a/ERRa Regulate Lactate Oxidation
(A) ERRa target genes involved in lactate oxidation.
(B) MDA436 cells were infected with adenoviruses expressing b-gal (negative control), wild-type PGC-1a, ERRa selective PGC-1a (2X9), or the nuclear receptor-
binding deficient PGC-1a (L2L3M) for 48 hr. RNA was harvested and the expression of ERRa target genes was analyzed by qRT-PCR.
(C) MDA436 cells were infected as in Figure 4B and whole-cell extracts were analyzed by immunoblotting to determine the expression of PGC-1a and ERRa.
b-actin was used as a loading control.
(D) MDA436 cells were transfected with either control (siCtrl) or ERRa (siERRa-A and siERRa-B) siRNAs for 24 hr, followed by infection of adenoviruses
expressing b-gal (negative control), wild-type PGC-1a, ERRa selective PGC-1a (2X9), or the nuclear receptor-binding deficient PGC-1a (L2L3M) for 48 hr. The
qRT-PCR data were normalized to expression of 36B4. The heatmaps were derived from qRT-PCR data using R software.
(legend continued on next page)
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GSH supplementation. It was also demonstrated that removal of
glutamine did not decrease lactate oxidation as measured by
14CO2 release from
14C-lactate, ruling out the possibility that
the failure of lactate alone to rescue cell viability in these assays
is a result of the inability of cells to oxidize lactate in the absence
of glutamine (Figure 3C). Indeed, it was observed that the
oxidation of lactate was actually increased when glutamine
was absent, a possible consequence of an increase in the
amount of lactate that was committed to oxidative metabolism
by the TCA cycle/OXPHOS to compensate for the reduced flux
of glutamine into this pathway. Similarly, the oxidation of gluta-
mine was increased in cells in the absence of lactate (data not
shown).
Inhibition of ERRa Attenuates Mitochondrial Oxidation
of Lactate
The ability of breast cancer cells to utilize lactate as a metabolic
substrate highlights the potential therapeutic utility of selectively
targeting mitochondrial metabolism. This, we hypothesized,
could be accomplished by inhibiting the activity of the ERRa,
an orphan nuclear receptor that is expressed in most cancers
that has been shown to play a key role in mitochondrial biogen-
esis and function (Gaillard et al., 2006). With respect to lactate
metabolism, it was significant that a reanalysis of the ERRa tran-
scriptome, reported previously (Chang et al., 2011), revealed that
the expression of the mRNAs encoding the monocarboxylate
transporter 1 (MCT1), lactate dehydrogenase B (LDHB), and
proteins involved in both the TCA cycle and OXPHOS were posi-
tively regulated by this receptor (Figure 4A, highlighted in red).
Thus, the impact of modulating ERRa activity on the expression
of genes involved in glycolysis, the TCA cycle, OXPHOS, and
pyruvate metabolism in multiple breast cancer cell lines was
undertaken.
Small molecule agonists for ERRa have not yet been identified,
making it difficult tomanipulate the activity of this receptor. How-
ever, we have previously demonstrated that this limitation can be
circumvented by expressing one of the obligate ERRa coregula-
tors (PGC1a or PGC1b) in target cells (Chang et al., 2011; Gail-
lard et al., 2006). As PGC1a/b can also serve as coregulators
for many other transcription factors, the specific role of ERRa
as a mediator of the PGC-1a/b induced changes was confirmed
using PGC-1a (or PGC-1b) mutants that (1) were engineered to
be highly selective for ERRa (2X9) or (2) were unable to interact
with any nuclear receptors (L2L3M) (Gaillard et al., 2006). Using
these previously validated tools, it was demonstrated that
PGC1a/ERRa upregulated the expression of most of the genes
involved in the TCA cycle, OXPHOS, and lactate metabolism in
MDA436 cells (Figures 4B and 4C) and in MDA231 and SKBR3
cells (Figure S4A). Two different siRNAs directed against ERRa
were used to demonstrate that this receptor was required for
the expression of the implicated genes in MDA436 cells (Figures
4D and 4E) and in MDA231 cells (Figure S4B). Not surprisingly,(E) MDA436 cells were infected as in Figure 4D, and whole-cell extracts were an
b-actin was used as a loading control.
(F) MDA436 cells were transfected with either control (siCtrl) or ERRa (siERRa) siR
with or without 10 mM sodium lactate. The cells were harvested on days as shosiRNA-mediated knock down of ERRa decreased oxygen con-
sumption (Figure S4D) and prevented lactate support of cell
viability in low glucose conditions (Figures 4F and S4C). Consid-
ering the results of several studies indicating that a significant
amount of ATP generated in cancer cells is derived from mito-
chondrial oxidative metabolism, it was a surprise that ERRa
knockdown had no significant effect on cell viability in glucose
replete conditions (Figures 4F and S4C). However, it was
observed that the decrease in oxygen consumption rate (OCR)
observed upon ERRa knockdown was accompanied by an in-
crease in the extracellular acidification rate (ECAR), indicative
of increased lactate secretion (Figures S4E and S4F). This
increase in extracellular lactate was likely due to increased
glycolysis as treatment of cells with an ERRa antagonist resulted
in increased glucose consumption and an increase in lactate
production in high glucose media (Figure S4G). Taken together,
the results of these experiments highlight the direct role of ERRa
in glucose/lactate oxidation and how decreased mitochondrial
function can be compensated for by increased glycolysis.
Inhibition of Mitochondrial Metabolism Using ERRa
Antagonists as a Therapeutic Approach in Cancer
The impact of two chemically and mechanistically distinct small
molecule inhibitors of ERRa (compound 29 [Cpd29] and XCT790)
on lactate-mediated rescue of glucose-deprivation induced cell
death was assessed. These studies revealed that both Cpd29
(Patch et al., 2011) and XCT790 (Willy et al., 2004) inhibited the
ability of lactate (or MP) to support cell viability in no/low glucose
conditions (Figures 5A and S5A–S5C) and attenuated lactate
oxidation (Figure 5B). It was also observed that the expression
of those genes required for lactatemetabolismwas also reduced
by ERRa inhibition (Figure 5C). As indicated above, ERRa likely
inhibits several processes that are involved in cancer patho-
genesis, but it is important to note that treatment with Cpd29
significantly reduced the flux of lactate into the TCA cycle as evi-
denced by a decrease in the enrichment of 13C-labeled lactate
into TCA cycle intermediates (Figures 5D and 5E). Decreased
flux of lactate into alanine, glutamate, and aspartate was
observed in the Cpd29 treated cells. Interestingly, lactate flux
into PEP, serine, and glycine were significantly increased in the
presence of Cpd29 (Figure S5D), a result that is consistent with
an increase in 13C-labeled pyruvate derived from 13C-lactate
(Figure S5E).
One of the most important effects of ERRa antagonism noted
in our untargeted metabolite analysis was the reduction in the
pool size of both GSH and the GSH precursor (g-L-glutamyl-L-
cysteine) in Cpd29 treated cells (Figure S5F). Although lactate
only contributes to about 15% of the total pool of GSH, it was
important to note that the flux of 13C lactate into GSH/GSSH
was decreased upon ERRa inhibition (Figure S5G). These data
suggest that in addition to inhibiting lactate oxidation, the cyto-
toxic activity of Cpd29 in low/no glucose conditions may alsoalyzed by immunoblotting to determine the expression of PGC-1a and ERRa.
NA for 48 hr, and cells were then changed to the indicated experimental media
wn, and cell numbers were determined by staining with Hoechst 33258.
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Figure 5. Pharmacological Inhibition of ERRa Impairs Lactate Oxidation
(A) MDA436 cells were cultured in the indicated media in the presence of Cpd29 and harvested on days as shown and cell numbers were determined.
(B) The generation of 14CO2 from [U-
14C]-lactate was measured from MDA436 cells cultured in glucose-free media containing [U-14C]-lactate for 24 hr in the
absence (DMSO) or presence of Cpd29. The data shown are representative of two independent experiments. The error bars represent SD (statistical significance
DMSO versus Cpd29) (**p < 0.05).
(C) MDA436 cells were pretreated with DMSO or Cpd29 for 24 hr in 12.5 mM glucose containing media and changed to glucose-fee media containing 10 mM
lactate. RNA was harvested 14, 24, and 48 hr later and the expression of ERRa target genes was analyzed by qRT-PCR. The heatmaps were generated using
R software.
(D) A schematic representation of 13C-lactate incorporation into TCA cycle intermediates. The black and red circles represent 12C and 13C, respectively.
(E) Mass isotopomer distribution of the TCA cycle intermediates in MDA436 cells pretreated with DMSO or Cpd29 for 40 hr in 12.5 mM glucose containing media
and changed to glucose-fee media containing 10 mM [U-13C]-lactate for 6 and 24 hr. The error bars represent SD of three experimental replicates (statistical
significance Veh versus Cpd29) (**p < 0.05).be attributable to its ability to interfere with the ability of cells to
handle oxidative (ROS) stress.
Whereas there is strong rationale for developing ERRa an-
tagonists for cancer, we also wanted to explore additional phar-
maceutical approaches that could be used to attenuate the
protective activity of lactate in cancer cells. Recently, metformin330 Cell Reports 15, 323–335, April 12, 2016and other biguanides, which disrupt mitochondrial function,
have received considerable attention as potential cancer che-
motherapeutics (Foretz et al., 2014). Thus, the ability of metfor-
min to impact lactate dependent support of cell viability in low/
no glucose conditions was assessed. The results of this study
in MDA436 breast cancer cells indicate that high concentration
A B
C D
Figure 6. Cancer Cells Are Resistant to PI3K/
mTOR Inhibitors when Utilizing Lactate
(A) MDA436 cells were cultured in 12.5 mM glucose
containing media or glucose-free media supple-
mented with 10 mM lactate for 4 days in the pres-
ence of PI3K/mTOR and PI3K inhibitors. BEZ235:
PI3K/mTOR inhibitor (0.5 mM), GDC0980: PI3K/
mTOR inhibitor (0.5 mM), LY294002: PI3K inhibitor
(10 mM), and GDC0941: PI3K inhibitor (0.5 mM). The
error bars represent SD.
(B) The generation of 14CO2 from [U-
14C]-lactate
was measured from MDA436 cells treated with
DMSO, 0.5 mM BEZ235, and 10 mM LY294002
for 24 hr. The data shown are representative
of two independent experiments. The error bars
represent SD.
(C) MDA436 cells cultured in glucose-free media
containing 10 mM lactate were treated with ERRa
antagonist Cpd29 and BEZ235 alone or in combi-
nation for 14 days. The cell numbers were deter-
mined by staining with Hoechst 33258.
(D) MDA436 cells cultured as in Figure 6C were
treated with ERRa antagonist Cpd29 and LY294002
alone or in combination for 14 days. The cell
numbers were determined by staining with Hoechst
33258.of metformin (1 mM), but not lower dose (50 mM), was effective in
this assay, consistent with the findings of others who have
reported a similar efficacy for this drug in cell viability assays
(Figure S5H). Although in very early development the potential
utility of themitochondrial pyruvate carrier (MPC) inhibitor (Schell
et al., 2014), UK5099, was also evaluated and was shown to
inhibit lactate mediated cell survival in vitro (Figure S5I). Thus,
while metformin and UK5099 have desirable activities, the effi-
cacy and elevated expression of ERRa in cancer make an-
tagonists of this receptor attractive for clinical development as
cancer therapeutics.
Cells Using Lactate as a Metabolic Substrate Are
Resistant to PI3K/mTOR Inhibitors
The anticancer efficacy of PI3K/mTOR inhibitors has been attrib-
uted in part to their ability to inhibit glucose uptake and/or
metabolism (DeBerardinis et al., 2008). Thus, given the ability
of cancer cells to switch between glycolytic and mitochondrial
oxidative metabolism, the efficacy of selected inhibitors as a
function of the metabolic status of cells was assessed. It was
noted that breast cancer cell growth in high glucose media
(12.5 mM) could be inhibited by BEZ235, GDC0980 (dual PI3K/
mTOR inhibitors), or LY294002 and GDC0941 (PI3K inhibitors).
However, when lactate was used as the primary metabolic
substrate, MDA436 cells were completely resistant to these
inhibitors (Figures 6A and S6A). A similar impact of lactate on
sensitivity to BEZ235 was observed in other breast cancer cell
lines evaluated under the same conditions (Figure S6B). The
very reproducible increase in cell number observed in PI3K/
mTOR inhibitors treated cells in the presence of lactate can
be attributed to increased lactate dependent activation of
mitogen-activated protein kinase (MAPK) and to the disruption
of the inhibitory feedback of AKT on MAPK upon the additionof PI3K/mTOR inhibitors (unpublished data). Lactate oxidation
was not influenced by the treatment of cells with the selected
PI3K/mTOR inhibitors, suggesting that by utilizing lactate,
cancer cells can bypass the need for glycolysis and are thus
less sensitive to PI3K/mTOR inhibitors (Figure 6B). It is thus
inferred that ERRa antagonists would block the adaptive re-
sponses that enable cells to escape PI3K/mTOR inhibition. As
shown, the resistance to BEZ235 or LY294002 observed in
breast cancer cells utilizing lactate (Figures 6C and 6D) or MP
(Figure S6C) could be attenuated by coaddition of the ERRa
antagonist Cpd29. Similar results were found when GDC0980
and GDC0941 were evaluated under the same conditions (Fig-
ures S6D and S6E) and when using a second ERRa antagonist,
XCT790 (Figures S6F–S6I). To confirm that it was the disruption
of mitochondrial function and not another component of ERRa
biology that was responsible for the killing of cells resistant to
PI3K/mTOR inhibitors, we demonstrated that metformin and
UK5099, at concentrations that blocked lactate utilization, func-
tioned in a similar manner as ERRa antagonists (Figures S6J–
S6L). Extension of these studies revealed that most cells that
exhibited a luminal breast cancer phenotype and which ex-
pressed PIK3CA mutant (i.e., MCF-7 cells) were exquisitely
sensitive to both PI3K/mTOR inhibitors and ERRa antagonists
under all conditions examined (Figures S6M and S6N). However,
as with theMDA436 cell model, we observed a similar resistance
to PI3K/mTOR inhibitors in other cell models of TNBC when
propagated in lactate, and that this resistance could be abro-
gated by cotreatment with Cpd29 (Figures S6O and S6P). It is
not clear as yet why the ability to utilize lactate confers upon
some cells, but not others, resistance to PI3K/mTOR inhibitors.
However, these studies do highlight the potential clinical utility
of combining ERRa antagonists with a PI3K/mTOR inhibitor in
treatments for TNBC and other cancers that are PI3Kwt.Cell Reports 15, 323–335, April 12, 2016 331
A B Figure 7. Analysis of ERRa Antagonist/
BEZ235 Combinations in Animal Models of
Breast Cancer
(A) Animals bearing MDA436 xenografts were
treated with Cpd29 (30 mg/kg/day), BEZ235
(10 mg/kg/day), or the combination and tumor
volume was measured during the course of the
experiment.
(B) Tumor weight was measured at the termination
of the experiment. The data are mean of tumor
volume in each experimental group (n = 12 per
group), and the error bars represent SEM (statis-
tical significance from single agent alone) (**p <
0.05).Increased Antitumor Activity by Combining an ERRa
Antagonist with BEZ235
There are several PI3K/mTOR inhibitors in clinical development
for the treatment of a variety of cancers, although it is clear
that their full potential is likely to be limited by dose-limiting tox-
icities (Bendell et al., 2015; Burris et al., 2010). Indeed, in a pilot
study in mice using BEZ235 (30–50 mg/kg/d, high dose), a dose
that is used in most published studies, we observed profound
toxicities consistent with those seen in ongoing clinical trials
(Burris et al., 2010). Considering these liabilities, it is clear that
there is an unmet medical need for combination regimens that
can increase the antitumor efficacy of PI3K/mTOR inhibitors
while sparing other organs/systems. The results of the studies
described thus far suggest that inhibition of ERRa function in
tumors may result in a significant increase in tumor sensitivity
to these targeted therapies. To test this hypothesis, the efficacy
of a low dose of BEZ235 alone (10mg/kg/d, low dose), or in com-
bination with Cpd29, on the growth of MDA436 xenografts was
assessed. The lower dose of BEZ235 used for these studies
did not cause any noticeable treatment-related toxicities. As
shown, tumor volume (Figure 7A) and final tumor weight (Fig-
ure 7B) in both the BEZ235 and Cpd29 treated mice were signif-
icantly reduced in comparison to those in the control (vehicle)
group. The most important observation was that the combina-
tion of BEZ235 and Cpd29 was much more effective than either
monotherapy alone. These data provide strong rationale for the
development of ERRa antagonists for use in combination thera-
pies for TNBC and possibly other cancers.
DISCUSSION
The observation that most oncogenes increase glucose uptake
and/or utilization supports the strongly held hypothesis that
increased reliance on glycolytic metabolism is an inherent prop-
erty of transformed cells. It has been determined, however, that
up to 90% of the ATP generated within some cancer cells is pro-
duced by mitochondria and that complete oxidation of glucose
can occur in as low as 0.5% oxygen (Chandel et al., 1996; Rum-
sey et al., 1990; Zu and Guppy, 2004). The results of the studies
presented herein indicate that intact mitochondrial function, and
the ability to oxidize lactate, confers upon breast cancer cells
the ability to survive under glucose limiting conditions. Notably,332 Cell Reports 15, 323–335, April 12, 2016inhibition of ERRa (using antagonists or siRNAs), or complex I
(using metformin) have minimal effects on cell growth/viability
in glucose replete conditions, but induce substantial apoptosis
in cells when grown at concentrations of glucose that exist in tu-
mors. It was further demonstrated that the ability to switch from
glucose to lactate as a respiratory substrate has a significant
impact on the efficacy of some drugs. Most significant was the
observation that PI3K or dual PI3K/mTOR inhibitors are without
effect in breast cancer cells when glucose is limiting and cells are
forced to oxidize lactate. These findings are in line with those of
others which have indicated that resistance to (1) inhibition of
Kras pathway in pancreatic cancer (Viale et al., 2014), (2) BRAF
inhibitors in melanoma (Haq et al., 2013), and (3) oxaliplatin
and 5-fluorouracil in colon cancer (Vellinga et al., 2015) are asso-
ciated with a shift to oxidative metabolism.
Lactate has been an enigmatic molecule in cancer biology,
and it remains unclear how it contributes to the pathobiology
of tumors. Given that its production increases intratumoral acid-
ification, it has been proposed that it is a liability to tumors, a
conclusion that is supported by the observation that most tu-
mors express carbonic anhydrase IX (Swietach et al., 2007).
However, the acidification in tumors is no different from that
which occurs in exercising muscle where it has no deleterious
effects, but rather may encourage a shift from glucose to fatty
acid metabolism (Philp et al., 2005). Indeed, our studies suggest
that the ability to produce and maintain the local concentration
of lactate may be beneficial to the viability of the tumor. This
contention is supported by the observation that under condi-
tions of glucose deprivation, lactate can be completely oxidized
by cancer cells, entering the TCA cycle and sustaining ATP
levels. Importantly, no evidence for lactate-supported gluco-
neogenesis was observed in our isotopomer analysis; further-
more, knock down of pyruvate carboxylase did not attenuate
the protective effect of lactate. It is important to note that
lactate supplementation did not protect against cell death in
all cancer cells examined in this study. We have as yet been
unable to define the specific pathways, proteins, or processes
that confer upon cells the ability to utilize lactate as a sole car-
bon source in glucose deprived conditions. However, we have
found that lactate utilization requires GSH and thus it may be
differences in the ability to produce the reducing equivalents
needed to accommodate the ROS production associated with
increased oxidation that determines whether or not lactate can
be utilized by cancer cells.
Our studies have focused primarily on lactate as a fuel source
in cancer cells, although the work of others has indicated that it
may also play a role as a signaling molecule. Recent work has
shown that lactate is a ligand for GPR81, a G protein-coupled re-
ceptor that is expressed in some cancer cell lines and in pancre-
atic tumors whose activation leads to increased expression of
the monocarboxylate transporters and increased lactate uptake
(Roland et al., 2014). We did not find appreciable expression of
this receptor in the cellular models that were used in our studies
and thus believe that this aspect of lactate biology is distinct from
that which we have described.
In addition to supporting lactate oxidation, mitochondrial ac-
tivity contributes to cancer pathogenesis by supporting glutami-
nolysis, fatty acid oxidation, and by regulating autophagy (Guo
and White, 2013; Wise et al., 2008). Cumulatively, these findings
reinforce the importance of the mitochondria as a therapeutic
target in cancer. Indeed, metformin, a safe and well-tolerated
medication and an inhibitor of mitochondrial complex I, inhibits
tumor growth in animals and is currently being explored as a can-
cer therapeutic, albeit at doses higher than those used for the
management of type II diabetes (Wheaton et al., 2014). Our
data suggest that small molecule antagonists of ERRa may be
another useful way to inhibit mitochondrial function in cancer
cells. This conclusion is supported by the observation that (1)
ERRa expression and activity is elevated in tumors, (2) the phe-
notypes manifest in ERRa knockout in mice are subtle, and (3)
the existing ERRa antagonists are well tolerated in animals. It
has been suggested previously that ERRa may regulate the
expression of genes involved in glycolysis, explaining some of
the beneficial activity of ERRa antagonists (Charest-Marcotte
et al., 2010). However, this was not observed in the cellular
models we studied and indeed we noticed a small, but robust,
increase in glycolysis upon administration of ERRa antagonists,
an effect that we have ascribed to a compensatory increase in
glycolysis. This conclusion is in line with the findings of others,
which revealed that cells can revert to glycolytic energy meta-
bolism upon the inhibition of PGC1a expression in cellular
models of melanoma and colon cancer (Lim et al., 2014; Vellinga
et al., 2015). Thus, we believe that ERRa antagonists, while influ-
encing multiple aspects of tumor biology, can also function as
cancer cell selective inhibitors of mitochondrial metabolism,
but they may also have to be used in combination with other
agents that target glycolysis.
One of the most remarkable findings in this study was that
when utilizing lactate, some breast cancer cells were found to
be completely insensitive to the actions of PI3K and dual PI3K/
mTOR inhibitors, suggesting that by relying more on oxidative,
as opposed to glycolytic metabolism, cells can bypass the inhib-
itory activity of targeted therapies. It was of particular interest that
weobserved that cells expressingPIK3CAmutationswereexqui-
sitely sensitive to these inhibitors regardless ofwhether theywere
grown in glucose or lactate. However, in cells expressing PI3Kwt,
sensitivity was only apparent in high glucose conditions. This
finding may explain in part the heterogeneous response to
this class of agents that has been observed in clinical trials. We
conclude that (1) metabolic flexibility limits the effectiveness ofinterventions that target specific aspects of metabolism, (2)
metabolic heterogeneity will likely impact response to drugs
that inhibit oncogenes/signaling pathways that target glycolysis,
and (3) the evaluation of drug efficacy in idealized metabolic
conditions in vitro has significant limitations. In conclusion, the
studies presented indicate that like in other metabolically active
tissues, lactate is an important respiratory substrate, and theabil-
ity to use it efficiently confers a growth advantage upon tumors.
EXPERIMENTAL PROCEDURES
Detailed experimental procedures, cell lines, and reagents used in this study
are provided in Supplemental Information.
Proliferation Assays
MDA436 (9,000 cells/well) were seeded in 96-well plates containing regular
RPMI (8% FBS and 2 mM glutamine) for 48 hr and subsequently replaced
with glucose-free RPMI (10% dialyzed FBS and 2 mM glutamine) supple-
mented with 10 mM sodium lactate or MP (time zero). Cells were harvested
2, 4, 6, 8, or 10 days after treatment. Cell numbers were determined by staining
with the DNA dye Hoechst 33258 (Sigma) and resulting fluorescence was read
at excitation 346 nm and emission 460 nm using a Fusion microplate reader
(PerkinElmer).
Xenograft Experiments
Animals were maintained in accordance with the NIH Guide for Care and Use
of Laboratory Animals, and all procedures were approved by the Duke Univer-
sity Institutional Animal Care and Use Committees. MDA436 cells (2.53 106) in
50% Matrigel (BD Biosciences) were injected into the mammary fat pad of
8-week-old female NOD.SCID.gamma (NSG) mice. When tumors reached
150 mm3, mice were randomized and treated once daily by oral gavage with
vehicle (10% NMP and 90% PEG300), BEZ235 (10 mg/kg/day), Cpd29
(30 mg/kg/day), or in combination. All drugs were solubilized in 1 volume of
N-methylpyrrolidone (NMP) and 9 volumes of PEG300. Tumor size was
measured with calipers three times a week, and tumor volume was calculated
as (width2 3 length)/2. Statistical comparison among groups was carried out
using two-way ANOVA followed by a Bonferroni multiple comparison test.
U-13C Lactate and U-13C Glutamine Isotopomer Analysis
MDA436 (3.5 3 105 cells/well) or HCC1937 (3 3 105 cells/well) cells were
seeded in 6-well plates containing regular RPMI for 48 hr and then replaced
with glucose-free RPMI (10% dialyzed FBS and 2 mM glutamine) supple-
mented with 10 mM sodium lactate. After incubation at 37C for 40 hr, cells
were washed with PBS. Glucose-free RPMI (10% dialyzed FBS and 2 mM
glutamine) containing 10 mM [U-13C] lactate or glucose and glutamine-free
DMEM (10% dialyzed FBS) containing 10 mM sodium lactate and 2 mM
[U-13C] glutamine were then added. After 6 and 24 hr, the metabolites were
extracted as described previously (Liu et al., 2014).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2016.03.026.
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